Harvard Bioscience Stock

Harvard Bioscience EBIT

The EBIT of Harvard Bioscience (HBIO) as of Jul 24, 2026 is -5.38 M USD. In the previous year, EBIT was 2.29 M USD — a change of -335.27% (lower).

EBIT

-5.38 MUSD

YoY

-335.27%

Last updated:

In 2026, Harvard Bioscience's EBIT was -5.38 M USD, a -335.27% increase from the 2.29 M USD EBIT recorded in the previous year.

The Harvard Bioscience EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2020
0.20 base
Jan 1, 2021
3.40 base
Jan 1, 2022
-4.70 base
Jan 1, 2023
2.29 base
Jan 1, 2024
-5.38 base
Jan 1, 2025 (e)
-50.18 base
Jan 1, 2026 (e)
3.47 base
Jan 1, 2027 (e)
0.00 base
YEAREBIT (M USD)
2027 est -
2026 est 3.47
2025 est -50.18
2024 -5.38
2023 2.29
2022 -4.70
2021 3.40
2020 0.20
2019 2.80
2018 4.80
2017 -0.60
2016 -1.10
2015 -0.90
2014 6.80
2013 3.70
2012 8.10
2011 8.90
2010 10.70
2009 8.60
2008 10.10
2007 9.50
2006 8.70
2005 7.90
Access this data via the Eulerpool API

Harvard Bioscience Revenue

Harvard Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
102.10 M USD
200,000.00 USD
-7.80 M USD
Jan 1, 2021
118.90 M USD
3.40 M USD
-300,000.00 USD
Jan 1, 2022
113.30 M USD
-4.70 M USD
-9.50 M USD
Jan 1, 2023
112.25 M USD
2.29 M USD
-3.42 M USD
Jan 1, 2024
94.14 M USD
-5.38 M USD
-12.41 M USD
Jan 1, 2025 (e)
87.62 M USD
-50.18 M USD
1.37 M USD
Jan 1, 2026 (e)
94.45 M USD
3.47 M USD
4.33 M USD
Jan 1, 2027 (e)
98.43 M USD
0.00 USD
9.12 M USD

Harvard Bioscience Margins

Harvard Bioscience stock margins

The Harvard Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Harvard Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Harvard Bioscience.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
56.81 %
0.20 %
-7.64 %
Jan 1, 2021
56.94 %
2.86 %
-0.25 %
Jan 1, 2022
54.99 %
-4.15 %
-8.38 %
Jan 1, 2023
59.15 %
2.04 %
-3.04 %
Jan 1, 2024
58.22 %
-5.71 %
-13.18 %
Jan 1, 2025 (e)
58.22 %
-57.28 %
1.56 %
Jan 1, 2026 (e)
58.22 %
3.67 %
4.59 %
Jan 1, 2027 (e)
58.22 %
0.00 %
9.27 %

Harvard Bioscience Stock analysis

What does Harvard Bioscience do? Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world. Harvard Bioscience is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Harvard Bioscience's EBIT

Harvard Bioscience's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Harvard Bioscience's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Harvard Bioscience's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Harvard Bioscience’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Harvard Bioscience stock

EBIT of Harvard Bioscience is -5.38 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Harvard Bioscience

All Key Metrics — Harvard Bioscience